In an EGFR‐mutant NSCLC tumor xenograft mouse model, DS‐1205c in combination with gefitinib, erlotinib or osimertinib significantly delayed the onset of tumor resistance to TKIs compared with TKI monotherapy (Daiichi Sankyo, data on file).12 Here, EGFR is linked to neoplasm.